Loading
ImmunoACT
The IIT Bombay spin-off that won India's first CAR-T approval in 2023 with NexCAR19 and has treated more than 600 patients at a tenth of Western prices.
Overview
ImmunoACT was established in 2018 as a spin-off from IIT Bombay, where Rahul Purwar's group had worked on a humanised CD19 CAR since 2013. Clinical development ran with Tata Memorial Centre: first patients were dosed at Tata Memorial Hospital in 2021 and the DCGI granted market authorisation for NexCAR19 (talicabtagene autoleucel) in 2023, India's first approved CAR-T therapy. The phase 1/2 study (64 enrolled at six centres) reported an overall response rate of 73% in 51 evaluable patients. The company reports more than 600 patients treated across over 130 authorised centres, a 98% manufacturing success rate, about 20 days from apheresis to infusion and a WHO-certified GMP facility with capacity for 750 patients a year, expanding to 1,500. It received a US patent in 2025 and in 2026 partnered with Cipla to supply South Africa, Algeria and Morocco.
Headquarters
Mumbai, IN
Scorecard
All companies#341of 1520 companies, score 11
- approved products +6
- targets +2
- modalities +2
- regions +1
1 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Type
Website
Founded
2018
Products
1ApprovedCAR-T (CD19, humanised)
Talicabtagene autoleucel · NexCAR19
India's first home-grown CAR-T cell therapy, approved in 2023 for relapsed leukaemia and lymphoma, made in Mumbai for roughly a tenth of what the same kind of treatment costs in the US.
People
3Rahul Purwar
Professor, Department of Biosciences and Bioengineering, IIT Bombay; founder, ImmunoACT
CAR-T cell engineeringImmunologyCell therapy manufacturing
The IIT Bombay immunologist whose laboratory designed India's first approved CAR-T therapy and who founded the company that makes it for a fraction of Western prices.
Hasmukh Jain
Professor of Medical Oncology (adult haematolymphoid), Tata Memorial Hospital
LymphomaAcute leukaemiaCAR-T cell therapy
First author of the phase 1/2 trial of India's first CAR-T therapy, which treated adults with relapsed lymphoma and leukaemia at six Indian centres.
Gaurav Narula
Professor of Paediatric Oncology, Tata Memorial Hospital
Paediatric oncologyChildhood leukaemiaCAR-T cell therapy
A paediatric oncologist at Tata Memorial who led the leukaemia arm of India's first CAR-T trials and runs national childhood leukaemia protocols.
Key papers
1Connected
22Similar pages
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Talicabtagene autoleucel, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines.
- TrialIMAGINE (varnimcabtagene autoleucel, Immuneel)
Shares Point-of-care and decentralised cell manufacturing, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines, CD19.
- TreatmentVarnimcabtagene autoleucel
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines.
- CompanyImmuneel Therapeutics
Shares Point-of-care and decentralised cell manufacturing, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanyCellogen Therapeutics
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- CompanyGenomeFrontier Therapeutics
Shares Autologous CAR-T manufacturing, batch by batch, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- Key paperUCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL
Shares Point-of-care and decentralised cell manufacturing, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- Key paperA National Cancer Grid pooled procurement initiative, India
Shares Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
cancers
fronts
technologies
targets
drugs
ApprovedCAR-T (CD19, humanised)
Talicabtagene autoleucel · NexCAR19
companies
institutions
trials
roadmaps
people
bottlenecks
key papers
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
immunoact.com · 1
Papers and guidelines, by DOI · 1
A source that has moved or gone is reported by the weekly link check. /audit/